JP2021516996A5 - - Google Patents
Info
- Publication number
- JP2021516996A5 JP2021516996A5 JP2020571337A JP2020571337A JP2021516996A5 JP 2021516996 A5 JP2021516996 A5 JP 2021516996A5 JP 2020571337 A JP2020571337 A JP 2020571337A JP 2020571337 A JP2020571337 A JP 2020571337A JP 2021516996 A5 JP2021516996 A5 JP 2021516996A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- polypeptide
- cells
- amino acid
- polypeptide according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023204147A JP2024037778A (ja) | 2015-09-11 | 2023-12-01 | 生物学的に関連する直交サイトカイン/受容体対 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562217364P | 2015-09-11 | 2015-09-11 | |
| US201662375089P | 2016-08-15 | 2016-08-15 | |
| US15/916,689 | 2018-03-09 | ||
| US15/916,689 US10869887B2 (en) | 2015-09-11 | 2018-03-09 | Biologically relevant orthogonal cytokine/receptor pairs |
| PCT/US2019/021451 WO2019173773A1 (en) | 2015-09-11 | 2019-03-08 | Biologically relevant orthogonal cytokine/receptor pairs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023204147A Division JP2024037778A (ja) | 2015-09-11 | 2023-12-01 | 生物学的に関連する直交サイトカイン/受容体対 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021516996A JP2021516996A (ja) | 2021-07-15 |
| JP2021516996A5 true JP2021516996A5 (cg-RX-API-DMAC7.html) | 2022-03-16 |
| JP7846963B2 JP7846963B2 (ja) | 2026-04-16 |
Family
ID=58240003
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018513275A Active JP7299021B2 (ja) | 2015-09-11 | 2016-09-07 | 生体関連の直交性サイトカイン/受容体ペア |
| JP2020571337A Active JP7846963B2 (ja) | 2015-09-11 | 2019-03-08 | 生物学的に関連する直交サイトカイン/受容体対 |
| JP2021180486A Active JP7495385B2 (ja) | 2015-09-11 | 2021-11-04 | 生体関連の直交性サイトカイン/受容体ペア |
| JP2023204147A Pending JP2024037778A (ja) | 2015-09-11 | 2023-12-01 | 生物学的に関連する直交サイトカイン/受容体対 |
| JP2024013400A Pending JP2024054175A (ja) | 2015-09-11 | 2024-01-31 | 生体関連の直交性サイトカイン/受容体ペア |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018513275A Active JP7299021B2 (ja) | 2015-09-11 | 2016-09-07 | 生体関連の直交性サイトカイン/受容体ペア |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021180486A Active JP7495385B2 (ja) | 2015-09-11 | 2021-11-04 | 生体関連の直交性サイトカイン/受容体ペア |
| JP2023204147A Pending JP2024037778A (ja) | 2015-09-11 | 2023-12-01 | 生物学的に関連する直交サイトカイン/受容体対 |
| JP2024013400A Pending JP2024054175A (ja) | 2015-09-11 | 2024-01-31 | 生体関連の直交性サイトカイン/受容体ペア |
Country Status (17)
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7299021B2 (ja) * | 2015-09-11 | 2023-06-27 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 生体関連の直交性サイトカイン/受容体ペア |
| BR112019018915A2 (pt) | 2017-03-15 | 2020-04-14 | Pandion Therapeutics Inc | imunotolerância direcionada |
| AU2018273914A1 (en) | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| KR102777151B1 (ko) | 2017-11-21 | 2025-03-05 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 인터루킨-2의 부분 효능제 |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| WO2020131547A1 (en) * | 2018-12-19 | 2020-06-25 | Iovance Biotherapeutics, Inc. | Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof |
| MX2021011258A (es) * | 2019-03-18 | 2021-12-10 | Biontech Cell & Gene Therapies Gmbh | Variantes de interleucina-2 (il2) y receptor de interleucina-2 (il2r) para la activacion especifica de celulas efectoras inmunitarias. |
| AU2020279240A1 (en) | 2019-05-20 | 2021-12-23 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
| CN114555634B (zh) * | 2019-08-13 | 2025-01-10 | 美国安进公司 | 用于扩增调节性t细胞的白介素-2突变蛋白 |
| WO2021050752A1 (en) * | 2019-09-11 | 2021-03-18 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric orthogonal receptor proteins and methods of use |
| CA3151471A1 (en) * | 2019-10-08 | 2021-04-15 | Gesa VOLKERS | Modified extracellular domain of granulocyte colony-stimulating factor receptor (g-csfr) and cytokines binding same |
| US11648296B2 (en) * | 2019-12-13 | 2023-05-16 | Synthekine, Inc. | IL-2 orthologs and methods of use |
| IL293978A (en) * | 2019-12-20 | 2022-08-01 | Regeneron Pharma | New il2 agonists and methods of using them |
| KR20220140514A (ko) | 2020-01-10 | 2022-10-18 | 브라이트 피크 테라퓨틱스 아게 | 변형된 il-2 폴리펩타이드 및 그의 용도 |
| CN115315273A (zh) * | 2020-01-14 | 2022-11-08 | 辛德凯因股份有限公司 | Il-2直向同源物及其使用方法 |
| CN115362168A (zh) | 2020-01-14 | 2022-11-18 | 辛德凯因股份有限公司 | 偏向化il2突变蛋白方法和组合物 |
| KR20220131529A (ko) * | 2020-01-14 | 2022-09-28 | 신테카인, 인크. | 변경된 icd stat 신호전달을 갖는 cd122 |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| BR112022017656A2 (pt) * | 2020-03-05 | 2022-10-18 | Univ Leland Stanford Junior | Variantes de il-2 concebidas |
| JP2023520572A (ja) * | 2020-04-06 | 2023-05-17 | シンセカイン インコーポレイテッド | オルソゴナルな受容体を発現するようにゲノムが改変されたヒト免疫細胞 |
| WO2021207290A1 (en) * | 2020-04-06 | 2021-10-14 | Synthekine, Inc. | Engineered immune cells |
| KR20230060514A (ko) * | 2020-09-01 | 2023-05-04 | 다케다 야쿠힌 고교 가부시키가이샤 | 인터루킨-2 뮤테인 및 이의 용도 |
| CN116529257A (zh) * | 2020-10-26 | 2023-08-01 | 尼普图恩生物科学有限公司 | 正交il-21受体/细胞因子系统 |
| WO2022093683A1 (en) * | 2020-10-26 | 2022-05-05 | Neptune Biosciences Llc | Orthogonal il-21 receptor/cytokine systems |
| US12012441B2 (en) | 2020-10-26 | 2024-06-18 | Neptune Biosciences Llc | Engineered human IL-21 cytokines and methods for using the same |
| EP4305054A4 (en) * | 2021-03-09 | 2025-03-19 | The Trustees of The University of Pennsylvania | SELECTIVE STIMULATION OF T CELLS IN SOLID TUMORS USING ONCOLYTIC VIRAL ADMINISTRATION OF ORTHOGONAL IL-2 |
| US20240182584A1 (en) * | 2021-04-02 | 2024-06-06 | The Board Of Trustees Of The Leland Stanford Junior University | Bispecific Molecules and Related Compositions and Methods |
| WO2022213208A1 (en) * | 2021-04-07 | 2022-10-13 | Provincial Health Services Authority | Modified granulocyte colony-stimulating factor (g-csf) and chimeric cytokine receptors binding same |
| KR20240034221A (ko) | 2021-07-09 | 2024-03-13 | 브라이트 피크 테라퓨틱스 아게 | 염증성 질환 및 자가면역 질환의 치료를 위한 변형된 il-2 폴리펩티드 |
| EP4370139A4 (en) * | 2021-07-14 | 2025-10-15 | Synthekine Inc | METHODS AND COMPOSITIONS FOR USE IN CELL THERAPY FOR NEOPLASTIC DISEASE |
| EP4402161A1 (en) | 2021-09-17 | 2024-07-24 | Parker Institute For Cancer Immunotherapy | Switch receptors using il-9 signaling domains |
| PE20242341A1 (es) * | 2022-04-04 | 2024-12-12 | Gammadelta Therapeutics Ltd | Blindaje genetico novedoso |
| EP4293040A1 (en) | 2022-06-19 | 2023-12-20 | ETH Zurich | Cell line for engineering cytokine receptors |
| CN121013867A (zh) * | 2023-06-07 | 2025-11-25 | Fbd生物制品有限公司 | 工程化的il-7变体及其使用方法 |
| WO2025245495A1 (en) * | 2024-05-24 | 2025-11-27 | Cz Biohub Sf, Llc | Selective sensitization of cancer cells to elimination by cytotoxic lymphocytes |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4902502A (en) * | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| EP1069917A4 (en) * | 1998-03-20 | 2005-02-09 | Genzyme Corp | NEW COMPLEMENTARY PAIRS OF RECEPTORS / LIGANDS AND ADOPTIVE IMMUNOTHERAPY USING THE SAME |
| US6955807B1 (en) * | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| US7666400B2 (en) | 2005-04-06 | 2010-02-23 | Ibc Pharmaceuticals, Inc. | PEGylation by the dock and lock (DNL) technique |
| US6926898B2 (en) * | 2000-04-12 | 2005-08-09 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP1454138B1 (en) * | 2001-12-04 | 2012-01-18 | Merck Patent GmbH | Immunocytokines with modulated selectivity |
| KR20070003934A (ko) * | 2004-03-05 | 2007-01-05 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템 |
| US20060199250A1 (en) * | 2005-03-04 | 2006-09-07 | Huimin Zhao | Method for generating a mutant protein which efficiently binds a target molecule |
| JP2009542592A (ja) | 2006-07-06 | 2009-12-03 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Il−2媒介性免疫応答の有効性を高める組成物および方法 |
| JP5703020B2 (ja) | 2007-08-24 | 2015-04-15 | ノボ ノルディスク ヘルス ケア アーゲー | タンパク質を選択的に修飾するための組成物と方法 |
| EP2560994B1 (en) * | 2010-04-08 | 2016-10-12 | JN Biosciences LLC | Antibodies to cd122 |
| WO2013074916A1 (en) * | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| LT2884999T (lt) * | 2012-08-20 | 2021-04-12 | Fred Hutchinson Cancer Research Center | Ląstelinės imunoterapijos būdas ir kompozicijos |
| US9434935B2 (en) * | 2013-03-10 | 2016-09-06 | Bellicum Pharmaceuticals, Inc. | Modified caspase polypeptides and uses thereof |
| EP2968450A4 (en) | 2013-03-15 | 2016-10-26 | Angelica Therapeutics Inc | MODIFIED TOXINS |
| SI2997141T1 (sl) | 2013-05-13 | 2023-04-28 | Cellectis | CD19 specifični himerni antigenski receptor in njegova uporaba |
| JP6640834B2 (ja) | 2014-08-11 | 2020-02-05 | デリニア, インコーポレイテッド | 自己免疫疾患の処置のために調節性t細胞を選択的に活性化させる改変il−2変異体 |
| IL304950A (en) * | 2015-04-10 | 2023-10-01 | Amgen Inc | Interleukin for the expansion of myotonic control T-2 cells |
| JP7299021B2 (ja) * | 2015-09-11 | 2023-06-27 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 生体関連の直交性サイトカイン/受容体ペア |
| CN107746831B (zh) | 2017-11-07 | 2019-04-23 | 南京北恒生物科技有限公司 | 具有化疗药物抗性的通用型cart/tcrt细胞及其构建方法 |
-
2016
- 2016-09-07 JP JP2018513275A patent/JP7299021B2/ja active Active
- 2016-09-07 KR KR1020247040181A patent/KR20250004916A/ko active Pending
- 2016-09-07 AU AU2016318621A patent/AU2016318621A1/en not_active Abandoned
- 2016-09-07 HK HK19100492.2A patent/HK1258138A1/zh unknown
- 2016-09-07 CN CN201680065667.7A patent/CN108430518A/zh active Pending
- 2016-09-07 WO PCT/US2016/050511 patent/WO2017044464A1/en not_active Ceased
- 2016-09-07 CA CA2998393A patent/CA2998393A1/en active Pending
- 2016-09-07 EP EP16844963.5A patent/EP3347056A4/en active Pending
- 2016-09-07 KR KR1020187010150A patent/KR102739782B1/ko active Active
- 2016-09-07 CN CN202311460072.XA patent/CN117659160A/zh active Pending
-
2018
- 2018-03-09 US US15/916,689 patent/US10869887B2/en active Active
-
2019
- 2019-02-28 US US16/289,274 patent/US11439664B2/en active Active
- 2019-03-08 EP EP19764492.5A patent/EP3761997A4/en active Pending
- 2019-03-08 KR KR1020207028947A patent/KR20210062591A/ko active Pending
- 2019-03-08 CN CN201980031023.XA patent/CN112272560B/zh active Active
- 2019-03-08 US US16/977,385 patent/US20210060068A1/en not_active Abandoned
- 2019-03-08 WO PCT/US2019/021451 patent/WO2019173773A1/en not_active Ceased
- 2019-03-08 JP JP2020571337A patent/JP7846963B2/ja active Active
- 2019-03-08 SG SG11202008780SA patent/SG11202008780SA/en unknown
- 2019-03-08 CN CN202510224041.7A patent/CN120209111A/zh active Pending
- 2019-03-08 IL IL277118A patent/IL277118B2/en unknown
- 2019-03-08 AU AU2019231997A patent/AU2019231997B2/en active Active
- 2019-03-08 IL IL313413A patent/IL313413A/en unknown
- 2019-03-08 MX MX2020009330A patent/MX428362B/es unknown
- 2019-03-08 CA CA3093472A patent/CA3093472A1/en active Pending
- 2019-03-08 BR BR112020018293-1A patent/BR112020018293A2/pt not_active Application Discontinuation
- 2019-03-08 RU RU2020133171A patent/RU2020133171A/ru unknown
- 2019-03-11 AR ARP190100597A patent/AR114687A1/es unknown
-
2020
- 2020-09-09 PH PH12020551417A patent/PH12020551417A1/en unknown
- 2020-10-05 ZA ZA2020/06168A patent/ZA202006168B/en unknown
- 2020-11-19 US US16/953,000 patent/US12005079B2/en active Active
-
2021
- 2021-11-04 JP JP2021180486A patent/JP7495385B2/ja active Active
-
2022
- 2022-07-26 US US17/815,092 patent/US20220354893A1/en not_active Abandoned
-
2023
- 2023-06-15 AU AU2023203727A patent/AU2023203727B2/en active Active
- 2023-12-01 JP JP2023204147A patent/JP2024037778A/ja active Pending
-
2024
- 2024-01-31 JP JP2024013400A patent/JP2024054175A/ja active Pending
- 2024-07-30 US US18/789,470 patent/US20240374645A1/en active Pending
-
2025
- 2025-08-12 US US19/298,037 patent/US20260108586A1/en active Pending
-
2026
- 2026-07-02 AU AU2026205249A patent/AU2026205249A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110818802B (zh) | 一种嵌合t细胞受体star及其应用 | |
| RU2020133171A (ru) | Биологически значимые ортогональные пары цитокинов/рецепторов | |
| US10725044B2 (en) | T cell receptors and immune therapy using the same | |
| CN108603200B (zh) | 优化的慢病毒转移载体及其用途 | |
| JP6422134B2 (ja) | キメラ抗原受容体 | |
| US12497453B2 (en) | ROR1 specific chimeric antigen receptors and their therapeutic applications | |
| CN107074929B (zh) | 嵌合自身抗体受体t细胞的组合物和方法 | |
| JP6639233B2 (ja) | Mage−a1を認識する高結合活性結合分子 | |
| BR112020024246A2 (pt) | pelo menos um polinucleotídeo recombinante, célula recombinante, receptor de antígeno quimérico, polinucleotídeo que codifica o receptor de antígeno quimérico, vetor, vírus, composição farmacêutica, e, método para tratar câncer | |
| JP6985934B2 (ja) | 操作された造血幹細胞/前駆細胞及び非tエフェクター細胞、ならびにその使用 | |
| JP2017530724A (ja) | 多様な多重抗原のターゲティングのための汎用的キメラ抗原受容体を発現する免疫細胞および該免疫細胞の製造方法ならびに該免疫細胞の、癌、感染症および自己免疫疾患の治療のための使用 | |
| AU2019370618C1 (en) | Bispecific polypeptides for engagement of CAR expressing immune cells with antigen presenting cells and uses thereof | |
| US20060263334A1 (en) | Therapeutic and diagnostic cloned MHC-unrestricted receptor specific for the MUC1 tumor associated antigen | |
| JP7606510B2 (ja) | Ebv-由来抗原に特異的なtcr構築物 | |
| CN115315270A (zh) | 工程化免疫细胞 | |
| AU2019406447A1 (en) | CD22-specific T cell receptors and adoptive T cell therapy for treatment of B cell malignancies | |
| JP7429462B2 (ja) | Ssx2抗原の短いペプチドを識別するt細胞受容体 | |
| JP2023529416A (ja) | キメラ抗原受容体細胞 | |
| HK40049020A (en) | Bispecific polypeptides for engagement of car expressing immune cells with antigen presenting cells and uses thereof | |
| CN115725504A (zh) | 工程化免疫细胞及其用途 | |
| CN118574843A (zh) | 以可检测的亲和力结合特异性肽的抗原识别构建体和对kras具有抗原特异性的t细胞受体以及相应的核酸序列、载体、宿主细胞、药物组合物和试剂盒 | |
| Powell Jr et al. | Genetically Engineered Antigen Specificity in T Cells for Adoptive Immunotherapy | |
| BR112016020518B1 (pt) | Receptor antigênico quimérico |